化工社化工社 化学情報印刷レポート · 研究参考用
1,2,7,8-テトラクロロジベンゾ-p-ジオキシン
2,3,6,7-テトラクロロジベンゾ-p-ジオキシン · 1,2,7,8-テトラクロロジベンゾ[b,e][1,4]ジオキシン · 2,3,6,7-テトラクロロジベンゾジオキシン · 1,2,7,8-テトラクロロジベンゾ[1,4]ジオキシン · 2,3,6,7-テトラクロロジベンゾ[b,e][1,4]ジオキシン · 1,2,7,8-テトラクロロジベンゾ-p-ジオキシン · 1,2,7,8-テトラクロロジベンゾジオキシン · 1,2,7,8-テトラクロロジベンゾ-P-ジオキシン標準液
識別子と物理属性
| CAS No. | 34816-53-0 |
|---|---|
| 分子式 | C12H4Cl4O2 |
| 平均分子量 | 322 g/mol |
| 単同位体質量 | 319.89654 g/mol |
| SMILES | Clc1cc2c(cc1Cl)Oc1c(ccc(Cl)c1Cl)O2 |
| InChIKey | YDZCLBKUTXYYKS-UHFFFAOYSA-N |
| PubChem CID | 36934 |
| ChEMBL | CHEMBL137849 |
| EC No. | 110-499-8 |
| DTXSID | DTXSID3073478 |
| 現地名 | 1,2,7,8-テトラクロロジベンゾ-p-ジオキシン |
化学・物理的性質
| XLogP | 6 |
|---|---|
| 極性表面積 | 18.5 |
| 水素結合供与体数 | 0 |
| 水素結合受容体数 | 2 |
| 回転可能結合数 | 0 |
| 重原子数 | 18 |
| 形式電荷 | 0 |
| 複雑度 | 316 |
| LogP（分配係数） | 6.38 |
| 融点 | 189.36°C (estimate) |
| 沸点 | 407.62°C (rough estimate) |
| 密度 | 1.6430 (estimate) |
| 屈折率 | 1.6430 (estimate) |
| ヘンリー定数 | 7.8×10-1 mol/(m3Pa) at 25℃, Wang and Wong (2002) |
| EPAの化学物質情報 | 1,2,7,8-Tetrachlorodibenzo-p-dioxin (34816-53-0) |
安全性と法規制
| GHS 分類 | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (100%) |
| Minimum Risk Level | Acute Oral: 0.0002 ug/kg/day (L134) Intermediate Oral: 0.00002 ug/kg/day (L134) Chronic Oral: 0.000001 ug/kg/day (L134) |
| Treatment | Treatment of CDD exposure may include washing the area of contact, GI decontamination, administering an IV, or forced alkaline diuresis. (L346) |
| 健康影響 | Exposure to large amounts of CDDs causes chloracne, a severe skin disease with acne-like lesions that occur mainly on the face and upper body. CDDs may also cause liver damage and induce long-term alterations in glucose metabolism and subtle changes in hormonal levels. In addition, studies have shown that CDDs may disrupt the endocrine system and weaken the immune system, as well as cause reproductive damage and birth defects, central and peripheral nervous system pathology, thyroid disorders, endometriosis, and diabetes. (L177, L178) |
| 暴露経路 | Oral (L177)inhalation(L177)dermal (L177) |
| 毒性の概要 | CDDs cause their toxic effects by binding to the aryl hydrocarbon receptor and subsequently altering the trascription of certain genes. The affinity for the Ah receptor depends on the structure of the specific CDD. The change in gene expression may result from the direct interaction of the Ah receptor and its heterodimer-forming partner, the aryl hydrocarbon receptor nuclear translocator, with gene regulatory elements or the initiation of a phosphorylation/dephosphorylation cascade that subsequently activates other transcription factors. The affected genes include several oncogenes, growth factors, receptors, hormones, and drug-metabolizing enzymes. The change in transcription/translation of these genes is believed to be the cause of most of the toxic effects of CDDs. (L177) |
| Signs and Symptoms | In addition to chloracne, CDD exposure causes skin rashes, discoloration, and excessive body hair. (L177) |
| Carcinogen Classification |
用途
使用
1,2,7,8-Tetrachlorodibenzo-p-dioxin is used as a standard in environmental testing and research into pesticides and impurities.